Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage

Clinica Chimica Acta

Volumn 411, Issue 7-8, 2010, Pages 459-466

  Takeuchi, Koji ^a   Tanaka, Akiko ^a   Kato, Shinichi ^a   Amagase, Kikuko ^a   Satoh, Hiroshi ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

COX 1 inhibition; COX 2 inhibition; Intestinal damage; NSAID; Pathogenic mechanism

Indexed keywords

16,16 DIMETHYLPROSTAGLANDIN E2; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; AMINOGUANIDINE; AMOXICILLIN; AMPICILLIN; ATROPINE; COLESTYRAMINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; MYELOPEROXIDASE; N(G) NITROARGININE METHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; ROFECOXIB; SALICYLIC ACID;

CELL PROTECTION; COMBINATION CHEMOTHERAPY; ENTEROBACTERIALES; ENZYME ACTIVITY; ENZYME INHIBITION; INTESTINE INJURY; INTESTINE MOTILITY; INTESTINE MUCOSA; INTESTINE ULCER; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPECIES INVASION; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; HUMANS; INDOMETHACIN; INTESTINE, SMALL; LACTONES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONES;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE;

EID: 77649192712     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.12.026     Document Type: Review

References (46)

1. Robert A., Asano T. Resistance of germ-free rats to indomethacin-induced intestinal inflammation. Prostaglandins 1977, 14:333-341.
2. Fang W.F., Broughton A., Jacobson E.D. Indomethacin induced intestinal inflammation. Am J Dig Dis 1977, 22:749-760.
3. Bjarnason I., Zanelli G., Smith T., et al. Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987, 93:480-489.
4. Whittle B.J.R. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 1981, 80:94-98.
5. Weissenborn U., Maedge S., Buettner D., Sewing K.F. Indomethacin-increased gastrointestinal lesions in relation to tissue concentration, food intake and bacterial invasion in the rat. Pharmacology 1985, 30:32-39.
6. Asako H., Kubes P., Wallace J.L., Granger D.N. Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol 1992, 262:G903-G908.
7. Yamada T., Deitch E., Specian R.D., Perry M.A., Sartor R.B., Grisham M.B. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993, 17:641-662.
8. Tanaka A., Kunikata T., Konaka A., Kato S., Takeuchi K. Dual action of nitric oxide in pathogenesis of indomethacin-induced small intestinal ulceration in rats. J Physiol Pharmacol 1999, 50:405-417.
9. Konaka A., Nishijima M., Tanaka A., Kato S., Takeuchi K. Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res 1999, 40:517-524.
10. 2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci 2002, 47:894-904.
11. Kargman S., Charlesion S., Cartwright M., et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1993, 111:445-454.
12. Xie W.L., Robertson D.L., Simmons D.L. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992, 25:249-265.
13. Seibert K., Zhang Y., Leahy K., et al. Pharmacological and biochemical demonstration of the role of cyclo-oxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A 1994, 91:12013-12017.
14. Langenbach R., Morham S.G., Tiano H.F., et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995, 83:483-492.
15. Chan C.C., Boyce S., Bridear C., et al. Pharmacology of a selective cyclooxygenase-2 inhibitor L-745337: a novel non-steroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non-human primate stomach. J Pharmacol Exp Ther 1995, 274:1531-1537.
16. - channels in the basolateral membrane of rat gastric parietal cells. Jpn J Physiol 1999, 49:365-372.
17. Feng L., Sun W., Xia Y., et al. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 1993, 307:361-368.
18. O'Neill G.P., Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS 1993, 330:156-160.
19. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., Otomo S. NS-398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclo-oxygenase (COX-2) activity in vitro. Prostaglandins 1994, 47:55-59.
20. Wallace J.L., McKnight W., Reuter B.K., Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000, 119:706-714.
21. Tanaka A., Araki H., Hase S., Takeuchi K. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal anti-inflammatory drugs. J Physiol Paris 2001, 95:21-27.
22. Tanaka A., Hase S., Miyazawa T., Takeuchi K. Up-regulation of COX-2 by inhibition of COX-1: a key to NSAID-induced intestinal damage. J Pharmacol Exp Ther 2002, 300:754-761.
23. Tanaka A., Hase S., Ohno R., Takeuchi K. Role of COX-1 and COX-2 inhibition in NSAID-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther 2002, 303:1248-1254.
24. Takahira Yuka, Izumi Nahoko, Tanaka Akiko, Takeuchi Koji Importance of bile acids in COX-2 and iNOS expressions as well as lesion formation in rat small intestines following administration of indomethacin: relation to farnesoid X receptors. Gastroenterology 2007, 132:A-565.
25. Takeuchi K., Hase S., Mizoguchi H., Komoike Y., Tanaka A. Protection by aspirin of indomethacin-induced small intestinal damage in rats: mediation by salicylic acid. J Physiol (Paris) 2001, 95:51-57.
26. Takeuchi K., Yokota A., Taniguchi M., Takahira Y., Tanaka A. Factors involved in up-regulation of inducible nitric oxide synthase in rat small intestine following administration of nonsteroidal antiinflammatory drugs. Dig Dis Sci 2006, 51:1250-1259.
27. Lam S.K., Cho C.H., Chen B.W., et al. Gastric cytoprotection by amoxicillin in the rat. J Gastroenterol Hepatol 1994, 9:514-518.
28. Ohno R., Yokota A., Tanaka A., Takeuchi K. Induction of small intestinal damage in rats following combined treatment with cyclooxygenase-2 and nitric oxide synthase inhibitors. J Pharmacol Exp Ther 2004, 310:821-827.
29. Takeuchi K., Miyazawa T., Tanaka A., Kato S., Kunikata T. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 2002, 66:30-41.
30. Watanabe T., Higuchi H., Kobata A., et al. Nonsteroidal anti-inflammatory drug-induced small intestinal damage is toll-like receptor 4 dependent. Gut 2008, 57:181-187.
31. Kunikata T., Miyazawa T., Kanatsu K., Kato S., Takeuchi K. Protective effect of thiaton, the anti-spasmodic drug, against indomethacin-induced intestinal ulceration in rats. Jpn J Pharmacol 2002, 88:45-54.
32. Boughton-Smith N., Evans S.M., Laszlo F., Whittle B.J.R., Moncada S. The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br J Pharmacol 1993, 110:1189-1195.
33. Tanaka A., Matsumoto M., Nakagiri A., Takeuchi K. Mechanism underlying up-regulation of COX-2 in rat small intestine under inhibition of COX-1: relation to intestinal hypermotility. J Gastroent Hepathol 2005, 20:38-45.
34. Whittle B.J.R., Laszlo F., Evans A.M., Moncada S. Inducible nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin. Br J Pharmacol 1995, 116:2286-2290.
35. Tanaka A., Mizoguchi H., Kunikata T., Miyazawa T., Takeuchi K. Protection by constitutively formed nitric oxide of intestinal damage induced by indomethacin in rats. J Physiol Paris 2001, 95:35-41.
36. Mizoguchi H., Tanaka A., Hase S., Takeuchi K. Lack of small intestinal toxicity of nitric oxide-releasing indomethacin, NCX-530, in rats. Aliment Pharmacol Ther 2001, 15:257-267.
37. Anthony A., Dhillon A.P., Nygard G., et al. Early histological features of small intestinal injury induced by indomethacin. Aliment Pharmacol Ther 1993, 7:29-40.
38. Anthony A., Pounder R.E., Dhillon A.P., Wakefield A.J. Vascular anatomy defines sites of indomethacin induced jejunal ulceration along the mesenteric margin. Gut 1997, 41:763-770.
39. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., Freeman B.A. Apparent hydroxyl radicals production by peroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990, 87:1620-1624.
40. Kobayashi O., Miwa H., Watanabe S., Tsujii M., Dubois R.N., Sato N. Cyclooxygenase-2 downregulates inducible nitric oxide synthase in rat intestinal epithelial cells. Am J Physiol 2001, 281:G688-G696.
41. Takeuchi K., Tanaka A., Suzuki K., Mizoguchi H., Araki H. Gastrointestinal sparing anti-inflammatory drugs: effects on ulcerogenic and healing responses. Current Pharmaceutical Design 2001, 7:49-71.
42. Robert A., Hanchar A.J., Lancaster C., Nezamis J.E. Antiulcer effect of aspirin. Gastroenterology 1973, 72:A-97.
43. Robert A. Gastric cytoprotection by sodium salicylate. Prostaglandins 1981, 21:139-146.
44. Komoike Y., Takeeda M., Tanaka A., Kato S., Takeuchi K. Prevention by parenteral aspirin of indomethacin-induced gastric lesions in rats: mediation by salicylic acid. Dig Dis Sci 2002, 47:1538-1545.
45. Endo H., Hosono K., Inamori M., et al. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol 2009, 44:544-549.
46. Shiotani A, Haruma K, Nishi R, Fujita M, Kamada T, Honda K, Kusunoki H, Hata J, Graham DY. Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage. Scand J Gastroenterol, in press. [doi:10.3109/00365520903453182].